Texas Prior Authorization Program
Clinical Criteria

Drug/Drug Class

Doxylamine/Pyridoxine

This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.

Clinical Criteria Information included in this Document

- Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

- Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules

- Logic diagram: a visual depiction of the clinical criteria logic

- Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable

- References: clinical publications and sources relevant to this clinical criteria

Note: Click the hyperlink to navigate directly to that section.

Revision Notes

Annual review by staff

Updated references

PAXPRESS™	**Doxylamine/Pyridoxine** **Drugs Requiring Prior Authorization**

The listed GCNs may not be an indication of Texas Medicaid Formulary coverage. To learn the current formulary coverage, visit txvendordrug.com/formulary/formulary-search.

| Drugs Requiring Prior Authorization	
Label Name	**GCN**
BONJESTA ER 20-20MG TABLET	42645
DICLEGIS DR 10-10MG TABLET	73860
DOXYLAMINE-PYRIDOXINE 10-10 MG TABLET	73860

1. Does the client have a diagnosis of nausea and vomiting associated with pregnancy in the last 180 days?

    [ ] Yes – Go to #2

    [ ] No – Deny

2. Is the request for less than or equal to (≤) 2 tablets per day?

    [ ] Yes – Approve (180 days)

    [ ] No (And the request is for Bonjesta) – Deny

    [ ] No (And the request is for Diclegis) – Go to #3

3. Is the request for less than or equal to (≤) 4 tablets per day?

    [ ] Yes – Approve (180 days)

    [ ] No – Deny

PAXPRESS™

Doxylamine/Pyridoxine

Clinical Criteria Logic Diagram

Deny Request

No, and the request is for Bonjesta

Step 1

Does the client have a diagnosis of nausea and vomiting associated with pregnancy in the last 180 days?

Yes →

Step 2

Is the request for ≤ 2 tablets per day ?

No, and the request is for Diclegis →

Step 3

Is the request for ≤ 4 tablets per day ?

No →

Deny Request

No ↓

Deny Request

Yes ↓

Approve Request (180 days)

Yes ↓

Approve Request (180 days)

PAXPRESS™

Doxylamine/Pyridoxine
Clinical Criteria Supporting Tables

Table 1 (diagnosis of nausea and vomiting associated with pregnancy) Required diagnosis: *1* Look back timeframe: *180* days	
ICD-10 Code	**Description**
O210	MILD HYPEREMESIS GRAVIDARUM
O211	HYPEREMESIS GRAVIDARUM WITH METABOLIC DISTURBANCE
O212	LATE VOMITING OF PREGNANCY
O218	OTHER VOMITING COMPLICATING PREGNANCY
O219	VOMITING OF PREGNANCY, UNSPECIFIED

PAXPRESS™

Doxylamine/Pyridoxine

Clinical Criteria References

1. 2025 ICD-10-CM Diagnosis Codes. 2025. Available at www.icd10data.com. Accessed on April 7, 2025.

2. Clinical Pharmacology [online database]. Tampa, FL: Elsevier/Gold Standard, Inc.; 2025. Available at www.clinicalpharmacology.com. Accessed on April 7, 2025.

3. Micromedex [online database]. Available at www.micromedexsolutions.com. Accessed on April 7, 2025.

4. Bonjesta Prescribing Information. Bryn Mawr, PA. Duchesnay USA, Inc. October 2022.

5. Diclegis Prescribing Information. Bryn Mawr, PA. Duchesnay USA, Inc. June 2023.

6. Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Obstet Gynecol 2018;131:e15. Reaffirmed 2022.

7. Smith JA, Fox KA, Clark SM. Nausea and vomiting of pregnancy: Treatment and outcome. In: UpToDate, Barss VA (Ed), Waltham, MA. Accessed April 7, 2025.

<table>
<tr><td></td><td align="right">**Doxylamine/Pyridoxine**

Publication History</td></tr>
</table>

The Publication History records the publication iterations and revisions to this document. Notes for the *most current revision* are also provided in the Revision Notes on the first page of this document.

Publication Date	Notes
10/25/2019	• Initial publication and presentation to the DUR Board
10/29/2019	• Updated with DUR Board recommendations
04/30/2021	• Annual review by staff • Added GCN for generic doxylamine-pyridoxine (73860) to drug table • Updated references
12/08/2023	• Annual review by staff • Updated references
07/31/2024	• Annual review by staff • Updated references
04/30/2025	• Annual review by staff • Updated references